Skip to main content

Table 4 Clinical trials of co-administration regimen in resistant patients

From: Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells

Combinational strategy

Malignancy

Reference/Identifier

Erlotinib+Gemcitabine

Pancreatic cancer

[100, 101]

Lapatinib+Capecitabine

Breast cancer

[102,103,104]

Nintedanib+Docetaxel

NSCLC

[106]

Erlotinib+Everolimus

Head and Neck squamous cell carcinoma

[141]

Erlotinib+Carboplatin

Ovarian cancer

[142]

Erlotinib+Topotecan

Solid tumor

[143]

Lapatinib+Epirubicin

Breast cancer

NCT 00753207

Sorafenib+Paclitaxel

Solid tumor

NCT 00572078

Back to article page

Molecular Cancer

ISSN: 1476-4598